Solara Active Pharma Sciences Limited

Informe acción NSEI:SOLARA

Capitalización de mercado: ₹36.6b

Solara Active Pharma Sciences Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Poorvank Purohit

Chief Executive Officer (CEO)

₹39.8m

Compensación total

Porcentaje del salario del CEO72.9%
Permanencia del CEO1.8yrs
Participación del CEOn/a
Permanencia media de la dirección1.8yrs
Promedio de permanencia en la Junta Directiva1.3yrs

Actualizaciones recientes de la dirección

Recent updates

The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Sep 13
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Jul 20
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Poorvank Purohit en comparación con los beneficios de Solara Active Pharma Sciences?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-₹5b

Jun 30 2024n/an/a

-₹6b

Mar 31 2024₹40m₹29m

-₹6b

Dec 31 2023n/an/a

-₹3b

Sep 30 2023n/an/a

-₹325m

Jun 30 2023n/an/a

-₹253m

Mar 31 2023₹5mn/a

-₹222m

Compensación vs. Mercado: La compensación total de Poorvank($USD471.43K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD273.81K).

Compensación vs. Ingresos: La compensación de Poorvank ha aumentado mientras la empresa no es rentable.


CEO

Poorvank Purohit (45 yo)

1.8yrs

Permanencia

₹39,800,000

Compensación

Mr. Poorvank Purohit serves as Chief Executive Officer of Solara Active Pharma Sciences Limited since February 03, 2023 and serves as its Director & Managing Director since July 2023. He started his career...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Poorvank Purohit
MD, CEO & Director1.8yrs₹39.80msin datos
Arun Baskaran
Chief Financial Officerless than a year₹700.00ksin datos
Mohan Muthunarayanan
COO & Executive Director2.3yrs₹3.80msin datos
Suddapalli Krishna
Company Secretary6.7yrs₹4.80msin datos
Arun Pillai
Founder & Non-Executive Directorno datasin datos5.71%
₹ 2.1b
Hero Velladurai
Chief Scientific Officerless than a yearsin datossin datos
V. Moorthy
Chief Quality Officerno datasin datossin datos

1.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de SOLARA no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Poorvank Purohit
MD, CEO & Director1.3yrs₹39.80msin datos
Mohan Muthunarayanan
COO & Executive Directorless than a year₹3.80msin datos
Arun Pillai
Founder & Non-Executive Director3.3yrssin datos5.71%
₹ 2.1b
Manish Gupta
Non-Executive Directorless than a yearsin datossin datos
Kausalya Santhanam
Independent Director6.6yrs₹1.50msin datos
Ramakrishnan Rajagopal
Independent Chairman6.6yrs₹1.50m0.010%
₹ 3.8m
Rajendra Srivastava
Independent Directorless than a year₹200.00ksin datos
Kartheek Raju
Non-Executive Non-Independent Director3.3yrssin datossin datos
Rajiv Nabar
Independent Directorless than a year₹400.00ksin datos

1.3yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de SOLARA no se considera experimentada (1.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.